Cambridge, UK, 26 May 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announced it has added four BRAF-resistant melanoma PDX (patient derived xenograft) models to its range of commercially available in vivo models to support drug efficacy studies.
PDX models are created by implanting cancerous tissue from a human primary tumor directly into immunodeficient mouse or rat models, enabling acceleration of oncology research or drug discovery and development programs. PDX models may be used to support studies including preclinical drug screening, preclinical combination therapeutics screening, or identification and analysis of biomarkers. The BRAF-resistant melanoma models available from Horizon have been highly characterized, including comprehensive patient histories, sequencing analysis data, and protein expression data.
The complex mix of genetics between individuals and even within a single tumor in cancer is an enormous challenge for cancer research and drug development, which ...
